Metabolic syndrome and Growth Differentiation Factor 15 in older adults

• Published in: GeroScience 2022-04, Vol.44 (2), p.867-880
• Main Authors: Carballo-Casla, Adrián, García-Esquinas, Esther, Buño-Soto, Antonio, Struijk, Ellen A., López-García, Esther, Rodríguez-Artalejo, Fernando, Ortolá, Rosario
• Format: Article
• Language: English
• Subjects: Aged; Albumin; Biomedical and Life Sciences; Blood pressure; Body fat; C-Reactive Protein; Cardiovascular disease; Cardiovascular diseases; Cardiovascular Diseases - etiology; Cell Biology; Cholesterol; Cytokines; Diabetes; Diabetes Mellitus; Fat metabolism; Geriatrics/Gerontology; Glucose; Glucose metabolism; Growth Differentiation Factor 15; High density lipoprotein; Humans; Hyperglycemia; Inflammation; Inflammation - complications; Insulin resistance; Life Sciences; Metabolic syndrome; Metabolic Syndrome - complications; Metabolic Syndrome - epidemiology; Microvasculature; Molecular Medicine; Older people; Original; Original Article; Regression analysis; Risk factors; Statistical analysis
• ISSN: 2509-2715; 2509-2723
• DOI: 10.1007/s11357-021-00370-w

Growth Differentiation Factor 15 (GDF-15) is a cytokine produced in response to tissue injury and inflammatory states that may capture distinct pathways between the risk factors aggregated within metabolic syndrome (MS) and the development of diabetes and cardiovascular disease. This work aims to study the association of MS and its components with GDF-15 among older adults, examining the roles of body fat distribution, glucose metabolism, and inflammation. Data were taken from the Seniors-ENRICA-2 study in Spain, which included 1938 non-institutionalized individuals aged ≥65 years free of diabetes and cardiovascular disease. MS was defined as the presence of ≥3 of the following components: high waist circumference, elevated fasting blood glucose levels, raised blood pressure, increased triglyceride levels, and low serum high-density lipoprotein (HDL) cholesterol. Statistical analyses were performed with linear regression models and adjusted for potential sociodemographic and lifestyle confounders. MS was associated with higher GDF-15 levels (fully adjusted mean increase [95% confidence interval] = 9.34% [5.16,13.7]). The MS components showing the strongest associations were high waist circumference (6.74% [2.97,10.6]), elevated glucose levels (4.91% [0.77,9.23]), and low HDL-cholesterol (8.13% [3.51,13.0]). High waist-to-hip ratio (7.07% [2.63,11.7]), urine albumin (12.1% [2.57,22.5]), and C-reactive protein (10.4% [3.89,17.3]) were also associated with increased GDF-15. In conclusion, MS was associated with higher GDF-15 levels in older adults. Abdominal obesity, hyperglycemia –possibly linked to microvascular disease, as inferred from elevated urine albumin–, low HDL-cholesterol, and inflammation were the main drivers of this association.